Medical Therapy for Heart Failure Associated With Pulmonary Hypertension

The past 2 decades have witnessed a >40% improvement in mortality for patients with heart failure and left ventricular systolic dysfunction. This success has coincided with the stepwise availability of drugs that target neurohormonal activationβ-adrenergic receptor blockers (β-blockers), ACE (ang...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation research 2019-05, Vol.124 (11), p.1551-1567
Hauptverfasser:	Zelt, Jason G.E, Chaudhary, Ketul R, Cadete, Virgilio J, Mielniczuk, Lisa M, Stewart, Duncan J
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiovascular Agents - adverse effects Cardiovascular Agents - therapeutic use Disease Progression Heart Failure - drug therapy Heart Failure - etiology Heart Failure - mortality Heart Failure - physiopathology Hemodynamics - drug effects Humans Hypertension, Pulmonary - complications Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - mortality Hypertension, Pulmonary - physiopathology Risk Factors Stem Cell Transplantation Treatment Outcome Ventricular Dysfunction, Right - drug therapy Ventricular Dysfunction, Right - etiology Ventricular Dysfunction, Right - mortality Ventricular Dysfunction, Right - physiopathology Ventricular Function, Right - drug effects Ventricular Remodeling - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!